N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate manufacturers
- BIBO3304 TFA
-
- $61.00
-
2026-09-10
- CAS:191868-14-1
- Purity: 99.50%
- Supply Ability: 10g
- BIBO3304 TFA
-
- $61.00
-
2026-07-15
- CAS:191868-14-1
- Purity: 99.50%
- Supply Ability: 10g
|
| | N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate Basic information |
| Product Name: | N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate | | Synonyms: | BIBO 3304 trifluoroacetate;BIBO 3304;BIBO 3304
(BIBO3304);BIBO3304 TFA;BIBO 3304 trifluoroa;(R)-2-(2,2-Diphenylacetamido)-5-guanidino-N-(4-(ureidomethyl)benzyl)pentanamide 2,2,2-trifluoroacetate;N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate;Inhibitor,Neuropeptide Y Receptor,subtype,BIBO3304,inhibit,insulin,NPY receptor,serum,hyperphagia,BIBO-3304,BIBO-3304 TFA,oral,BIBO3304 TFA,refeeding,BIBO 3304 | | CAS: | 191868-14-1 | | MF: | C31H36F3N7O5 | | MW: | 643.67 | | EINECS: | | | Product Categories: | | | Mol File: | 191868-14-1.mol | ![N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate Structure](CAS/20210111/GIF/191868-14-1.gif) |
| | N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate Chemical Properties |
| storage temp. | Store at +4°C | | solubility | <75.77mg/ml in DMSO; <75.77mg/ml in ethanol | | form | solid | | color | White | | InChIKey | FBMCYYWIBYEOST-NETKZVBLNA-N | | SMILES | C(F)(F)(F)C(=O)O.C(C1C=CC=CC=1)(C1C=CC=CC=1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC1C=CC(CNC(=O)N)=CC=1 |&1:23,r| |
| | N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate Usage And Synthesis |
| Uses | BIBO 3304 Trifluoroacetate is a high affinity NPY1-R antagonist, that inhibits NPY- and fasting-induced feeding in vivo following central administration. blockade of Y1 receptors may offer a novel anabolic treatment option for improving bone mass. | | in vivo | BIBO3304 (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting[1].
BIBO3304 (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY[1].
BIBO3304 (0.5μM; p.o.) significantly increases serum insulin levels[2]. | Animal Model: | Adult male Chbb:Thom rats weighing between 300 and 340 g[1] | | Dosage: | 30 μg | | Administration: | bilateral paraventricular nucleus injection | | Result: | Attenuated the hyperphagia following fasting, especially during the first 2 h of refeeding.
|
| Animal Model: | 7-week-old C57BL/6JAusb mice[2] | | Dosage: | 0.5μM | | Administration: | p.o. | | Result: | Significantly increased serum insulin levels.
|
| | IC 50 | NPY Y1 receptor |
| | N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamideditrifluoroacetate Preparation Products And Raw materials |
|